OpenEvidence Surges to $15 Billion Valuation Despite Accuracy and Ad Concerns
The medical AI startup OpenEvidence has achieved a massive $15 billion valuation as healthcare providers increasingly adopt its search tool. Despite its rapid growth and widespread clinical use, the platform faces ongoing scrutiny regarding its diagnostic accuracy and reliance on pharmaceutical advertisements, raising important questions about the intersection of commercial interests and medical technology.
Source: Ars Technica